Shire buys ViroPharma in $4.2 billion deal

  • Posted: Monday, November 11, 2013 10:13 p.m.

LONDON (AP) – Drug maker Shire says it is buying the rare disease biopharmaceutical company ViroPharma in a deal worth $4.2 billion.

Shire PLC will pay $50 a share, a 27 percent premium on last week’s closing price. ViroPharma makes CINRYZE, which treats hereditary angioedema, a disease characterized by recurrent attacks of swelling of the skin or mucous membranes. It can be painful, disfiguring and potentially life-threatening.

Dublin-based Shire says it believes that of the approximately 8,000 patients in the United States with the disease, it is actively managed in only about 3,500 patients.

Shire’s CEO, Dr. Flemming Ornskov, said Monday that the acquisition of ViroPharma, which is based in Exton, Pennsylvania, is consistent with the objective of strengthening the company’s rare disease portfolio and brings a growth driving product to the company.

Investors in Shire welcomed the deal, bidding up its stock 4.2 percent to 117 pence on the London Stock Exchange.

Comments { }

Commenting rules: Do not post offensive, racial or violent messages. Responsibility for the statements posted lies with the commenter, not www.aikenstandard.com. Click 'report abuse' for any comments that you feel should be removed from the site. However, www.aikenstandard.com is not obligated to remove any comment posted on the site. Moderators do not have the ability to edit comments. Read the terms of use.